apbioinc

PRECLINICAL ANTIBODY PIPELINE & PARTNERING OPPORTUNITY

 
 
 
Program Product Target / MOA Major Indication
IBI302
(Out-licensed, IND filed)
Bi-specific Undisclosed
AP101
(Out-licensed, expected IND filing in Q3,2018)
Bi-functional Undisclosed
AP105 Mono-specific antibody Checkpoint antagonist Immuno-oncology
AP116 Mono-specific antibody Co-stimulatory Receptor Immuno-oncology
AP117 Mono-specific antibody Co-stimulatory Receptor Immuno-oncology
AP118 Mono-specific antibody Inhibitory Checkpoint Immuno-oncology
AP119 Mono-specific antibody Tumor microenvironment Immuno-oncology
AP120 Mono-specific antibody Antigen presentation Immuno-oncology
AP201 Bi-specific antibody T cell activation, expansion, survival, memory Immuno-oncology
AP505 Bi-specific antibody T cell activation + tumor infiltration Immuno-oncology